Reducing Cancer Recurrence in Patients with Newly Diagnosed Multiple Myeloma

Recruiting · Phase 3 · Plasma Cell Myeloma and related conditions · 45 states

Check if I qualify View on ClinicalTrials.gov

About this trial

This study looks at how well a combination of four medicines works for adults with newly diagnosed multiple myeloma, a type of blood cancer. The main goal is to see if adding bortezomib to the usual three-drug treatment can help patients live longer and keep the cancer from coming back. The trial compares the effects of this four-drug combination to a standard three-drug combination.

The trial is identified by NCT04566328. It is a Phase 3 trial, which means it is looking closely at how well the treatments work and their safety. The study is regulated by the FDA, and it aims to include about 1,450 participants.

Who can join

Adults aged 18 and older can join this trial. Both men and women are welcome. Participants must have a newly diagnosed case of multiple myeloma and be in good health, with specific test results confirming their condition. The trial team will check to see if each person meets the requirements before they can participate.

Conditions

Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Participants are randomly placed into one of three groups. One group gets the standard treatment with three drugs. Another group receives a combination of four drugs, including bortezomib. The last group gets the same treatment as the first group but in a different order. Everyone will receive treatment for 9 cycles, and some will continue on maintenance therapy afterward.